FTX Digital Markets Partners with Solidus Labs for Trade Surveillance and Transaction Monitoring Services
FTX Digital Markets (“FTX”), the Bahamian subsidiary of FTX Trading Ltd., today announced that it has partnered with Solidus Labs, a category-definer for crypto risk monitoring, to provide market surveillance and transaction monitoring across FTX’s platform. As part of the partnership, FTX will deploy Solidus’ HALO platform, which provides risk monitoring, fraud-prevention and compliance services for digital assets.
“FTX Digital Markets has always been committed to providing our users with industry-leading products and services, while also promoting full transparency and holding ourselves to the standards commonly found in legacy finance,” said Ryan Salame, Co-CEO of FTX Digital Markets. “Solidus’ crypto-native approach, commitment to enabling transparency within the crypto ecosystem, and tools tailored for digital asset trade monitoring and surveillance makes the partnership an obvious choice. We are looking forward to working with the Solidus team to position our users for success by providing market-leading regulatory, compliance and security services.”
Solidus HALO is currently used to monitor more than 1 trillion events per day across more than 150 markets, protecting more than 25 million retail and institutional entities. It will enable FTX to access risk and compliance programs in one platform, while also utilizing behavioral-based detection models powered by machine-learning to address a range of crypto-specific threats and alerts. Advanced investigative tools, case management capabilities, 24/7 real-time monitoring and more than 200 integration points supported by HALO will provide FTX with insight into market integrity and allow it to identify potential risks across on-chain and off-chain data. The platform also amplifies FTX’s compliance capabilities amidst an evolving regulatory landscape.
“FTX is leading the charge towards safer crypto markets, driving public and institutional adoption, and taking the industry forward,” added Asaf Meir, Solidus Labs’ Founder and Chief Executive. “We’re delighted to support their effort through our crypto-native tools, and to continue working together to enable the potential of crypto to make finance more accessible, transparent and efficient, by mitigating the new risks.”
FTX Digital Markets
FTX Digital Markets is the Bahamian subsidiary of FTX Trading Ltd., owner and operator of FTX, a leading cryptocurrency exchange built by traders for traders. FTX Digital Markets offers users regulated access to FTX's industry-leading derivatives, options, volatility products, as well as other FTX products and services. To learn more, please visit: https://ftx.com/
Solidus Labs
Solidus Labs is the category-definer for crypto-native triple T (T3) market integrity solutions - trade surveillance, transaction monitoring, and threat intelligence. Our mission is to enable safe crypto trading throughout the investment journey across all centralized and DeFi markets. As the founder of industry leading initiatives like the Crypto Market Integrity Coalition and DACOM Summit, and in everything we do, Solidus is deeply committed to ushering in the financial markets of tomorrow. To learn more, please visit: https://soliduslabs.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005469/en/
Contact information
FTX Digital Markets Media
Peter Padovano
M Group Strategic Communications (on behalf of FTX)
646.859.5953
ftx@mgroupsc.com
Solidus Labs Media
Trevor Davis
Gregory FCA for Solidus Labs
443.248.0359
trevor@gregoryfca.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra ® with MDR Certification and New Expanded Indication for Body5.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs, décolletage, and upper arms. Sculptra can be used across these areas to address varied treatment goals – from improving skin quality (including the improvement in cellulite appearance), to enhancing firmness, as well as lift, projection, and contouring.1-5 Sculptra’s versatility allows practitioners to meet each patient’s unique needs, delivering natural-looking, long-lasting improvements across face and body. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204988559/en/ Meeting the moment: evolving patient needs As aesthetic expectations shift, patients are seeking more holistic
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 03:40:00 EET | Press release
Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge formats designed for different group styles and expectat
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 02:00:00 EET | Press release
Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helical Fusion will further accelerate development under its flagship program, the Helix Program—a comprehensive roadmap to achieve the world’s first commercially viable fu
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Xsolla Integrates MVola as a Payment Method to Enable Instant, Card-Free Payments for Gamers in Madagascar’s Mobile-First Market4.12.2025 22:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced that MVola, Madagascar’s number one digital wallet, is now available as a payment option for players across the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204268075/en/ Chris Hewish, President of Xsolla Madagascar is a fast-growing, mobile-first market of 32 million people, where digital wallets are the primary driver of daily transactions. MVola, recently licensed as a digital bank, has established itself as the leading wallet in the country, with over 10 million users and powering more than 1 billion transactions annually. By adding MVola as a payment method to its portfolio, Xsolla removes the friction of card payments, enabling players to pay seamlessly with a trusted local method they already know and use every day. Key benefits of the MVola integration include: Instant confirmations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom